AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02902289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg/5 mL oral suspension
Study NCT02902289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOMENT 200 mg coated tablet
Study NCT01875172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Description: Comparison of bupropion SR or placebo + smoking cessation counseling
Study NCT01875172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01875172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling
Study NCT01875172 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation counseling
Study NCT01834196 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Swept-Source Optical Coherence Tomography
Description: Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
Study NCT01708122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg in 1 mL intranasal spray
Study NCT01708122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Sodium Chloride 0.9% intranasal spray
Study NCT01030679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: 0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
Study NCT01030679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 1mg
Description: 1 mg/tablet, orally, 1 tablet once daily for 8 weeks
Study NCT01030679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 2mg
Description: 2 mg/tablet, orally, 1 tablet once daily for 8 weeks
Study NCT01030679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, 1 tablet once daily for 8 weeks
Study NCT04256603 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin
Description: Timing of gabapentin initiation
Study NCT00643864 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mirror training
Description: Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests.
Study NCT03487237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ddimer testing
Description: Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
Study NCT02282618 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Sympathetic Blockade
Study NCT03611829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Intervention
Study NCT03611829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Study NCT03611829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study NCT02102178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapestry
Description: A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges.
Study NCT02102178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular occupation therapy
Description: All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
Study NCT02102178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular occupation therapy
Description: All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
Study NCT02102178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weaving a scarf on a nail frame
Description: Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length.
Study NCT04256603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No gabapentin
Description: No gabapentin
Study NCT00841893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mustard (dijon)
Description: The specific spice added to a brunch meal
Study NCT00841893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo added to a brunch meal
Study NCT00494858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy - focused (CBT-EF)
Description: Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
Study NCT00494858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy - broad (EB)
Description: Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
Study NCT00732628 — intervention group
Intervention type: DEVICE
Intervention: Boomerang closure device
Description: Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
Study NCT04507061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: runcaciguat
Description: Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.
Study NCT04507061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham-titrated dose of matching placebo will be administered orally once a day.
Study NCT02833480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone group
Study NCT02833480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide group
Study NCT02833480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol group
Study NCT01320267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single port laparoscopic right hemicolectomy
Description: above procedure using Roticulating instruments (from Covidien)
Study NCT00594529 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Liver resection for metastatic liver lesions
Study NCT04182503 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a multi-city observational cohort study without intervention.
Study NCT01177605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
Description: Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
Study NCT01177605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
Description: Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
Study NCT01281007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 125 mg every 12 hours for 5 days
Study NCT01281007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciclovir
Description: Aciclovir 200 mg every 4 hours fo 5 days
Study NCT00861835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROSE
Description: rapid on-site evaluation by cytopathology
Study NCT04408261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buqitongluo Granule
Description: Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Study NCT04408261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buqitongluo Granule Placebo
Description: Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Study NCT04408261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
Study NCT04408261 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
Study NCT00519155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD05 and open flap debridement
Description: recombinant human GDF-5 coated onto ß-tricalcium phosphate
Study NCT00519155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement alone
Study NCT02752646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac 0.3%
Description: Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
Study NCT02752646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
Study NCT02076750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Study NCT02076750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Study NCT02102178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domino game
Description: Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand.
Study NCT04981483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative surgery for uterus in placenta accreta
Description: After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle\[outside in-in out then out in-in out\] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
Study NCT03236636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
Study NCT03417336 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: prostatic boost in brachytherapy with high dose rate (HDR)
Description: prostatic boost in brachytherapy with high dose rate (HDR)
Study NCT03417336 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: prostatic boost in brachytherapy with high dose rate (HDR)
Description: prostatic boost in brachytherapy with high dose rate (HDR)
Study NCT00402363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters
Study NCT00402363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03245970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours
Description: Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
Study NCT03245970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 60 mg orally daily
Description: Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
Study NCT03245970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 25 mg daily
Description: Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
Study NCT00388453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dx-pH Probe
Description: 24 hour ph monitoring
Study NCT00388453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dx-pH Probe
Description: 24 hour ph monitoring
Study NCT00388453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manometry
Description: procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
Study NCT00388453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manometry
Description: procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
Study NCT03236636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HUACHANSU PIAN
Description: HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
Study NCT03397810 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy
Description: 10 Gy in 5 fractions of 2 Gy on 5 consecutive days
Study NCT06404385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static computer-assisted guided surgery with analogic guide
Description: coDiagnostix9® planning software
Study NCT06404385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static computer-assisted guided surgery with CAD-CAM surgical guide
Description: coDiagnostix9® planning software
Study NCT01850667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)
Study NCT04395118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed Outreach
Description: The investigators will randomize elevated LFT patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
Study NCT03458065 — intervention group
Intervention type: DEVICE
Intervention: ICD
Description: Implantable Cardioverter Defibrillator
Study NCT01594866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 20mg and 30mg p.o. daily, 6 weeks
Study NCT01594866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: escitalopram
Description: escitalopram 20mg and 30mg p.o. daily, 6 weeks
Study NCT01594866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
Study NCT01594866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: escitalopram
Description: escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
Study NCT01415154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar TMS
Description: NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
Study NCT03182166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab (Optimization)
Description: Increase dose of golimumab.~* For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~* For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks.
Study NCT03182166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rectosigmoidoscopy
Description: Rectosigmoidoscopy will be realized for calculated Mayo score
Study NCT03182166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
Study NCT01475578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-1
Description: STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
Study NCT01475578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergoloid Mesylates tablet
Description: Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
Study NCT01119482 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MenAfriVac™
Description: Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
Study NCT03546933 — intervention group
Intervention type: DEVICE
Intervention: VitalScan Magnetocardiograph
Description: A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
Study NCT01205256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: 0.25mg/kg IV of racemic methadone at the induction of anesthesia.
Study NCT02170389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02170389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo partial or radical nephrectomy
Study NCT02170389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003
Description: Given ID